Clinical implications of globally emerging azole resistance in Aspergillus fumigatus

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 371, Issue 1709, 2016, Pages

  Meis, Jacques F ^a,b   Chowdhary, Anuradha ^c   Rhodes, Johanna L ^d   Fisher, Matthew C ^d   Verweij, Paul E ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF DELHI   (India)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Aspergillus fumigatus; Azole resistance; Epidemiology; Fungicides; Treatment; Worldwide emergence

Indexed keywords

DISEASE INCIDENCE; DISEASE TREATMENT; DRUG RESISTANCE; EPIDEMIOLOGY; FUNGAL DISEASE; FUNGICIDE; FUNGUS; GLOBAL PERSPECTIVE; MORTALITY; MUTATION; PATHOGEN;

ANIMALIA; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; FUNGI; FUSARIUM;

ANTIFUNGAL AGENT; FUNGICIDE; PYRROLE DERIVATIVE;

ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG EFFECTS; GENETICS; PHENOTYPE; PHYSIOLOGY; VETERINARY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; DRUG RESISTANCE, FUNGAL; FUNGICIDES, INDUSTRIAL; PHENOTYPE;

EID: 84992474617     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2015.0460     Document Type: Review

References (93)

1. Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, Ullmann AJ, Dimopoulos G, Lange C. 2016 Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur. Respir. J. 47, 45–68. (doi:10.1183/13993003.00583-2015)
2. Kosmidis C, Denning DW. 2015 The clinical spectrum of pulmonary aspergillosis. Thorax 70, 270–277. (doi:10.1136/thoraxjnl-2014-206291)
3. Taccone FS et al. 2015 Epidemiology of invasive aspergillosis in critically ill patients: clinical presentation, underlying conditions, and outcomes. Crit. Care 19, 7. (doi:10.1186/s13054-014-0722-7)
4. Wauters J et al. 2012 Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. Intensive Care Med. 38, 1761–1768. (doi:10.1007/s00134-012-2673-2)
5. Patterson TF et al. 2016 Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 63, e1–e60. (doi:10.1093/cid/ciw326)
6. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodríguez-Tudela JL. 2003 A point mutation in the 14-alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47, 1120–1124. (doi:10.1128/AAC.47.3.1120-1124.2003)
7. Van der Linden JWM, Warris A, Verweij PE. 2011 Aspergillus species intrinsically resistant to antifungal agents. Med. Mycol. 49, S82–S99. (doi:10.3109/13693786.2010.499916)
8. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009 Azole resistance in Aspergillus fumigatus: a side effect of environmental fungicide use? Lancet Infect. Dis. 9, 789–795.
9. Chowdhary A, Sharma C, Hagen F, Meis JF. 2014 Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol. 9, 697–711. (doi:10.2217/fmb.14.27)
10. Chowdhary A, Sharma C, Hagen F, Meis JF. 2015 Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Front. Microbiol. 6, 428. (doi:10.3389/fmicb.2015.00428)
11. Maertens JA et al. 2016 Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomisedcontrolled, non-inferiority trial. Lancet 387, 760–769. (doi:10.1016/S0140-6736(15)01159-9)
12. Liss B et al. 2015 Our 2015 approach to invasive pulmonary aspergillosis. Mycoses 58, 375–382. (doi:10.1111/myc.12319)
13. Hiemenz JW et al. 2010 Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur. J. Clin. Microbiol. Infect. Dis. 29, 1387–1394. (doi:10.1007/s10096-010-1013-0)
14. Cornely OA, Meems L, Herbrecht R, Viscoli C, van Amsterdam RG, Ruhnke M. 2015 Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. Mycoses 58, 58–64. (doi:10.1111/myc.12274)
15. Viscoli C et al. 2009 An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J. Antimicrob. Chemother. 64, 1274–1281. (doi:10.1093/jac/dkp355)
16. Marr KA et al. 2015 Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann. Intern. Med. 162, 81–89. (doi:10.7326/M13-2508)
17. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, Warnock DW, Kelly SL. 1997 Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41, 1364–1368.
18. Verweij PE, Te Dorsthorst DT, Rijs AJ, De Vries-Hospers HG, Meis JF. 2002 Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J. Clin. Microbiol. 40, 2648–2650. (doi:10.1128/JCM.40.7.2648-2650.2002)
19. Dannaoui E, Persat F, Monier MF, Borel E, Piens MA, Picot S. 1999 In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. J. Antimicrob. Chemother. 44, 553–555. (doi:10.1093/jac/44.4.553)
20. Verweij PE, Mellado E, Melchers WJ. 2007 Multipletriazole–resistant aspergillosis. N. Engl. J. Med. 356, 1481–1483. (doi:10.1056/NEJMc061720)
21. Snelders E et al. 2008 Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5, e219. (doi:10.1371/journal.pmed.0050219)
22. Camps SM, Rijs AJ, Klaassen CH, Meis JF, O’Gorman CM, Dyer PS, Melchers WJ, Verweij PE. 2012 Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J. Clin. Microbiol. 50, 2674–2680. (doi:10.1128/JCM.00335-12)
23. Verweij PE et al. 2015 International expert opinion on the management of infection caused by azoleresistant Aspergillus fumigatus. Drug Resist. Update 21–22, 30–40. (doi:10.1016/j.drup.2015.08.001)
24. Verweij PE, Chowdhary A, Melchers WJ, Meis JF. 2016 Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin. Infect. Dis. 62, 362–368. (doi:10.1093/cid/civ885)
25. Fraczek MG, Bromley M, Buied A, Moore CB, Rajendran R, Rautemaa R, Ramage G, Denning DW, Bowyer P. 2013 The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 68, 1486–1496. (doi:10.1093/jac/dkt075)
26. Meneau I, Coste AT, Sanglard D. 2016 Identification of Aspergillus fumigatus multidrug transporter genes and their potential involvement in antifungal resistance. Med. Mycol. 54, 616–627. (doi:10.1093/mmy/myw005)
27. Monk BC et al. 2014 Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. Proc. Natl Acad. Sci. USA 111, 3865–3870. (doi:10.1073/pnas.1324245111)
28. Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJ. 2010 Azole resistance profile of amino acid changes in Aspergillus fumigatus cyp51A based on protein homology modeling. Antimicrob. Agents Chemother. 54, 2425–2430. (doi:10.1128/AAC.01599-09)
29. Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, Melchers WJ. 2012 Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob. Agents Chemother. 56, 10–16. (doi:10.1128/AAC.05088-11)
30. Howard SJ, Pasqualotto AC, Anderson MJ, Leatherbarrow H, Albarrag AM, Harrison E, Gregson L, Bowyer P, Denning DW. 2013 Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis. Mycoses 56, 434–441. (doi:10.1111/myc.12047)
31. Zhang J, Debets AJ, Verweij PE, Melchers WJ, Zwaan BJ, Schoustra SE. 2015 Asexual sporulation facilitates adaptation: the emergence of azole resistance in Aspergillus fumigatus. Evolution 69, 2573–2586. (doi:10.1111/evo.12763)
32. Verweij PE, Zhang J, Debets AJM, Meis JF, van de Veerdonk FL, Schoustra SE, Zwaan B, Melchers WJG. 2016 In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management. Lancet Infect. Dis. 16, In press, S1473-3099(16)30138-4.
33. Ahmad S, Joseph L, Hagen F, Meis JF, Khan Z. 2015 Concomitant occurrence of itraconazole-resistant and-susceptible strains of Aspergillus fumigatus in routine cultures. J. Antimicrob. Chemother. 70, 412–415. (doi:10.1093/jac/dku410)
34. Kolwijck E, van der Hoeven H, de Se´vaux RG, Ten Oever J, Rijstenberg LL, van der Lee HA, Zoll J, Melchers WJ, Verweij PE. 2016 Voriconazolesusceptible and voriconazole-resistant Aspergillus fumigatus coinfection. Am. J. Respir. Crit. Care Med. 193, 927–929. (doi:10.1164/rccm.201510-2104LE)
35. Gsaller F et al. 2016 Sterol biosynthesis and azole tolerance is governed by the opposing actions of SrbA and the CCAAT binding complex. PLoS Pathog. 12, e1005775. (doi:10.1371/journal.ppat.1005775)
36. Van der Linden JW et al. 2015 Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg. Infect. Dis. 21, 1041–1044. (doi:10.3201/eid2106.140717)
37. Vermeulen E, Maertens J, De Bel A, Nulens E, Boelens J, Surmont I, Mertens A, Boel A, Lagrou K. 2015 Nationwide surveillance of azole resistance in Aspergillus diseases. Antimicrob. Agents Chemother. 59, 4569–4576. (doi:10.1128/AAC.00233-15)
38. Fuhren J, Voskuil WS, Boel CH, Haas PJ, Hagen F, Meis JF, Kusters JG. 2015 High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients. J. Antimicrob. Chemother. 70, 2894–2898. (doi:10.1093/jac/dkv177)
39. de Fontbrune FS, Denis B, Meunier M, Garcia-Hermoso D, Bretagne S, Alanio A. 2014 Iterative breakthrough invasive aspergillosis due to TR(34)/L98H azole-resistant Aspergillus fumigatus and Emericella sublata in a single hematopoietic stem cell transplant patient. Transpl. Infect. Dis. 16, 687–691. (doi:10.1111/tid.12231)
40. Burgel PR et al. 2012 High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob. Agents Chemother. 56, 869–874. (doi:10.1128/AAC.05077-11)
41. Jensen RH, Hagen F, Astvad KM, Tyron A, Meis JF, Arendrup MC. 2016 Azole resistant Aspergillus fumigatus in Denmark: a laboratory based study on resistance mechanisms and genotypes. Clin. Microbiol. Infect. 22, 570.e1-9. (doi:10.1016/j.cmi.2016.04.001)
42. Brillowska-Dąbrowska A, Mroczyńska M, Nawrot U, Włodarczyk K, Kurzyk E. 2015 Examination of cyp51A and cyp51B expression level of the first Polish azole resistant clinical Aspergillus fumigatus isolate. Acta Biochim. Pol. 62, 837–839. (doi:10.18388/abp.2015_1143)
43. Lazzarini C, Esposto MC, Prigitano A, Cogliati M, De Lorenzis G, Tortorano AM. 2015 Azole resistance in Aspergillus fumigatus clinical isolates from an Italian culture collection. Antimicrob. Agents Chemother. 60, 682–685. (doi:10.1128/AAC.02234-15)
44. Steinmann J et al. 2015 Emergence of azoleresistant invasive aspergillosis in HSCT recipients in Germany. J. Antimicrob. Chemother. 70, 1522–1526. (doi:10.1093/jac/dku566)
45. Howard SJ et al. 2009 Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15, 1068–1076. (doi:10.3201/eid1507.090043)
46. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. 2012 Isolation of multipletriazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J. Antimicrob. Chemother. 67, 362–366. (doi:10.1093/jac/dkr443)
47. Chowdhary A, Sharma C, van den Boom M, Yntema JB, Hagen F, Verweij PE, Meis JF. 2014 Multi-azoleresistant Aspergillus fumigatus in the environment in Tanzania. J. Antimicrob. Chemother. 69, 2979–2983. (doi:10.1093/jac/dku259)
48. Badali H et al. 2013 Environmental study of azoleresistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran. Mycoses 56, 659–563. (doi:10.1111/myc.12089)
49. Ahmad S, Khan Z, Hagen F, Meis JF. 2014 Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait. Environ Res. 133, 20–26. (doi:10.1016/j.envres.2014.05.009)
50. Kidd SE, Goeman E, Meis JF, Slavin MA, Verweij PE. 2015 Multi-triazole-resistant Aspergillus fumigatus infections in Australia. Mycoses 58, 350–355. (doi:10.1111/myc.12324)
51. Özmerdiven GE, Ak S, Ener B, Ağca H, Cilo BD, Tunca B, Akalın H. 2015 First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey. J. Infect. Chemother. 21, 581–586. (doi:10.1016/j.jiac.2015.04.012)
52. Wu C-J, Wang H-C, Lee J-C, Lo H-J, Dai C-T, Chou P-H, Ko W-C, Chen Y-C. 2015 Azole-resistant Aspergillus fumigatus isolates carrying TR34/L98H mutations in Taiwan. Mycoses 58, 544–549. (doi:10.1111/myc.12354)
53. Chen Y et al. 2016. Epidemiology and molecular characterizations of azole resistance in clinical and environmental Aspergillus fumigatus from China. Antimicrob. Agents Chemother. Antimicrob. Agents Chemother. 60, In press, pii: AAC.01005-16.
54. Wiederhold NP et al. 2016 First detection of TR34/L98H and TR46/Y121F/T289A cyp51 mutations in Aspergillus fumigatus isolates in the United States. J. Clin. Microbiol. 54, 168–171. (doi:10.1128/JCM.02478-15)
55. Pelaez T, Monteiro MC, Garcia-Rubio R, Bouza E, Gomez-Lopez A, Mellado E. 2015 First detection of Aspergillus fumigatus azole-resistant strain due to cyp51A TR46/Y121F/T289A in an azole-naive patient in Spain. New Microbes New Infect. 6, 33–34. (doi:10.1016/j.nmni.2015.04.005)
56. Lavergne R-A, Morio F, Favennec L, Dominique S, Meis JF, Gargala G, Verweij PE, Le Pape P. 2015 First description of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France. Antimicrob. Agents Chemother. 59, 4331–4335. (doi:10.1128/AAC.00127-15)
57. Hagiwara D, Takahashi H, Fujimoto M, Sugahara M, Misawa Y, Gonoi T, Itoyama S, Watanabe A, Kamei K. 2016 Multi-azole resistant Aspergillus fumigatus harboring cyp51A TR46/Y121F/T289A isolated in Japan. J. Infect. Chemother. 22, 577–579. (doi:10.1016/j.jiac.2016.01.015)
58. Le Pape P, Lavergne RA, Morio F, Alvarez-Moreno C. 2016 Multiple Fungicide-driven alterations in azoleresistant Aspergillus fumigatus, Colombia, 2015. Emerg. Infect. Dis. 22, 156–157. (doi:10.3201/eid2201.150978)
59. Lescar J, Meyer I, Akshita K, Srinivasaraghavan K, Verma C, Palous M, Mazier D, Datry A, Fekkar A. 2014 Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole. J. Antimicrob. Chemother. 69, 3244–3247. (doi:10.1093/jac/dku316)
60. Van der Linden JW et al. 2011 Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007–2009. Emerg. Infect. Dis. 17, 1846–1854. (doi:10.3201/eid1710.110226)
61. Van der Linden JW et al. 2013 Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin. Infect. Dis. 57, 513–520. (doi:10.1093/cid/cit320)
62. Lavergne RA, Chouaki T, Hagen F, Toublanc B, Dupont H, Jounieaux V, Meis JF, Morio F, Le Pape P. 2016. Home environment as a source of lifethreatening azole-resistant Aspergillus fumigatus in immunocompromised patients. Clin. Infect. Dis. accepted for publication (CID 83151).
63. Verweij PE. 2016 Azole resistance in Aspergillus fumigatus. Chapter 4.5.7 In NethMap 2015. Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands (eds SC de Greeff, JW Mouton, AF Schoffelen). Bergen, The Netherlands: SWAB, pp. 128–131.
64. Selmecki A, Forche A, Berman J. 2006 Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313, 367–370. (doi:10.1126/science.1128242)
65. Camps SM, Dutilh BE, Arendrup MC, Rijs AJ, Snelders E, Huynen MA, Verweij PE, Melchers WJ. 2012 Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLoS One 7, e50034. (doi:10.1371/journal.pone.0050034)
66. Valsecchi I, Mellado E, Beau R, Raj S, Latgé JP. 2015 Fitness studies of azole-resistant strains of Aspergillus fumigatus. Antimicrob. Agents Chemother. 59, 7866–7869. (doi:10.1128/AAC.01594-15)
67. Mavridou E, Meletiadis J, Jancura P, Abbas S, Arendrup MC, Melchers WJ, Heskes T, Mouton JW, Verweij PE. 2013 Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates. PLoS ONE 8, e72280. (doi:10.1371/journal.pone.0072280)
68. Pringle A, Baker DM, Platt JL, Latge JP, Taylor JW. 2005 Cryptic speciation in the cosmopolitan and clonal human pathogenic fungus Aspergillus fumigatus. Evolution 59, 1886–1899. (doi:10.1111/j.0014-3820.2005.tb01059.x)
69. O’Gorman CM, Fuller H, Dyer PS. 2009 Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus. Nature 457, 471–474. (doi:10.1038/nature07528)
70. Rydholm C, Szakacs G, Lutzoni F. 2006 Low genetic variation and no detectable population structure in Aspergillus fumigatus compared to closely related Neosartorya species. Eukaryot. Cell 5, 650–657. (doi:10.1128/EC.5.4.650-657.2006)
71. Swilaiman SS, O’Gorman CM, Balajee SA, Dyer PS. 2013 Discovery of a sexual cycle in Aspergillus lentulus, a close relative of A. fumigatus. Eukaryot. Cell 12, 962–969. (doi:10.1128/EC.00040-13)
72. Abdolrasouli A, Rhodes J, Beale MA, Hagen F, Rogers TR, Chowdhary A, Meis JF, Armstrong-James D, Fisher MC. 2015 Genomic context of azole resistance mutations in Aspergillus fumigatus determined using whole-genome sequencing. MBio 6, e00536.
73. Chowdhary A et al. 2012 Clonal expansion and emergence of environmental multiple-triazoleresistant Aspergillus fumigatus strains carrying the TR34/L98H mutations in the cyp51A gene in India. PLoS ONE 7, e52871. (doi:10.1371/journal.pone.0052871)
74. Chang H, Ashu E, Sharma C, Kathuria S, Chowdhary A, Xu J. 2016 Diversity and origins of Indian multitriazole resistant strains of Aspergillus fumigatus. Mycoses 59, 450–466. (doi:10.1111/myc.12494)
75. Takahashi-Nakaguchi A et al. 2015 Genome sequence comparison of Aspergillus fumigatus strains isolated from patients with pulmonary aspergilloma and chronic necrotizing pulmonary aspergillosis. Med. Mycol. 53, 353–360. (doi:10.1093/mmy/myv003)
76. Snelders E, Camps SM, Karawajczyk A, Schaftenaar G, Kema GH, van der Lee HA, Klaassen CH, Melchers WJ, Verweij PE. 2012 Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS ONE 7, e31801. (doi:10.1371/journal.pone.0031801)
77. Snelders E, Huis In’t Veld RA, Rijs AJ, Kema GH, Melchers WJ, Verweij PE. 2009 Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75, 4053–4057. (doi:10.1128/AEM.00231-09)
78. Chowdhary A, Kathuria S, Xu J, Meis JF. 2013 Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 9, e1003633. (doi:10.1371/journal.ppat.1003633)
79. Kwon-Chung KJ, Sugui JA. 2013 Aspergillus fumigatus—what makes the species a ubiquitous human fungal pathogen? PLoS Pathog. 9, e1003743. (doi:10.1371/journal.ppat.1003743)
80. Paul RA, Rudramurthy SM, Meis JF, Mouton JW, Chakrabarti A. 2015 A novel Y319H substitution in Cyp51c associated with azole resistance in Aspergillus flavus. Antimicrob. Agents Chemother. 59, 6615–6619. (doi:10.1128/AAC.00637-15)
81. Arendrup MC, Jensen RH, Grif K, Skov M, Pressler T, Johansen HK, Lass-Flörl C. 2012 In vivo emergence of Aspergillus terreus with reduced azole susceptibility and a cyp51A M217I alteration. J. Infect. Dis. 206, 981–985. (doi:10.1093/infdis/jis442)
82. Nivoix Y et al. 2008 Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47, 1176–1184. (doi:10.1086/592255)
83. Seyedmousavi S, Brüggemann RJ, Meis JF, Melchers WJ, Verweij PE, Mouton JW. 2015 Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model. Antimicrob. Agents Chemother. 59, 2855–2866. (doi:10.1128/AAC.04907-14)
84. Meis JF et al. 2015 Multicenter surveillance of azole-resistant Aspergillus fumigatus isolates in nonacademic teaching hospitals in the Netherlands. Mycoses 58(Suppl 4), 60.
85. Lestrade PP et al. 2016 Diagnosis and management of aspergillosis in the Netherlands: a national survey. Mycoses 59, 101–107. (doi:10.1111/myc.12440)
86. Clinical and Laboratory Standards Institute. 2008 Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd edn. Document M38-A2. Wayne PA, USA: Clinical Laboratory Standards Institute.
87. Arendrup MC, Guinea J, Cuenca-Estrella M, Meletiadis J, Mouton JW, Lagrou K, Howard SJ. 2016 Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST DEFINITIVE DOCUMENT E.DEF 9.3. See http://www.eucast.org/ast_of_fungi/methodsinanti fungalsusceptibilitytesting/susceptibility_testing_of_moulds/.
88. Langridge PJ, Sheehan RL, Denning DW. 2016 Microbial yield from physiotherapy assisted sputum production in respiratory outpatients. BMC Pulm. Med. 16, 23. (doi:10.1186/s12890-016-0188-2)
89. van der Linden JW, Snelders E, Arends JP, Daenen SM, Melchers WJ, Verweij PE. 2010 Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. J. Clin. Microbiol. 48, 1478–1480. (doi:10.1128/JCM.02221-09)
90. Denning DW et al. 2011 High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin. Infect. Dis. 52, 1123–1129. (doi:10.1093/cid/cir179)
91. Chong GL, van de Sande WW, Dingemans GJ, Gaajetaan GR, Vonk AG, Hayette MP, van Tegelen DW, Simons GF, Rijnders BJ. 2015 Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J. Clin. Microbiol. 53, 868–874. (doi:10.1128/JCM.03216-14)
92. White PL, Posso RB, Barnes RA. 2015 An analytical and clinical evaluation of the PathoNostics AsperGeniusw Assay for detection of invasive aspergillosis and resistance to azole antifungal drugs when testing serum samples. J. Clin. Microbiol. 53, 2115–2121. (doi:10.1128/JCM.00667-15)
93. Verweij PE, Arendrup MC, Denning DW, Kullberg BJ, Meis JF, Arikan-Akdagli S. 2017 Aspergillus guideline: Azole and amphotericin B resistance in Aspergillus, in preparation.